Scholarlink

Background <p>Quantifying the impact of malaria vaccines on outpatient malaria burden in children is of interest to many countries introducing either of the World Health Organization (WHO)-recommended vaccines (RTS,S/AS01 [RTS,S] or R21/Matrix-M [R21]). The cluster randomized implementation of RTS,S by the Kenya Ministry of Health during the Malaria Vaccine Implementation Programme (MVIP) provided a unique opportunity to measure the impact of RTS,S on uncomplicated malaria cases reported through routine malaria case surveillance data in western Kenya.</p> Methods <p>From 23 implementing and 23 comparison subcounties in western Kenya, monthly numbers of confirmed uncomplicated malaria cases among individuals under 5 years of age (&lt; 5y) and 5 years of age and older (≥ 5y) were extracted from the Kenya Health Management Information System, stored in a DHIS2 instance. Facilities that reported data ≥ 11 months per year from January 2015 through December 2022 (132 implementing, 139 comparison) were included in the analysis. Prevaccination data (January 2015–December 2019) were used to predict counterfactual case counts during the evaluation period (January 2020–December 2022), beginning when the first children vaccinated under MVIP became age-eligible for the third dose. Models of &lt; 5y malaria cases included a covariate for ≥ 5y malaria cases to control for non-RTS,S malaria control measures. The impact was estimated as the difference between predicted and observed cases across implementing and comparison areas.</p> Results <p>The proportion of vaccine eligible children (RTS,S doses at 6, 7, 9, and 24 months) among all children &lt; 5y was small at the start of MVIP but was estimated to reach 60% by December 2022. During the 3-year evaluation period following dose-3 age-eligibility, &lt; 5y malaria cases were 2.3% lower than predicted in non-implementing facilities and 13.8% lower in implementing facilities, a reduction of 11.6%. The reduction was 5.6% during the first year of follow-up, increasing to 8.2% after two years.</p> Conclusion <p>This analysis revealed that routine health data, although age-aggregated to both vaccine eligible and noneligible children &lt; 5 years, demonstrated a reduction in malaria cases throughout the evaluation period. A further reduction in cases was observed as more vaccine-eligible children comprised the under 5 population. High quality routine data can be used to monitor vaccine impact on clinical malaria.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Malaria Vaccine Implementation Programme reduced clinical malaria in Kenya, 2020 to 2022

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月15日

查看全文
  • John A. Painter,
  • Erika Wallender,
  • Andrew N. Hill,
  • Mary Hamel,
  • Rafiq Okine,
  • Eliane Furrer,
  • Rose Jalang’o,
  • Kibor K. Keitany,
  • Simon Kariuki,
  • Isabella Nyang’au,
  • Brian Seda,
  • Aaron M. Samuels,
  • Nelli Westercamp

摘要

Background

Quantifying the impact of malaria vaccines on outpatient malaria burden in children is of interest to many countries introducing either of the World Health Organization (WHO)-recommended vaccines (RTS,S/AS01 [RTS,S] or R21/Matrix-M [R21]). The cluster randomized implementation of RTS,S by the Kenya Ministry of Health during the Malaria Vaccine Implementation Programme (MVIP) provided a unique opportunity to measure the impact of RTS,S on uncomplicated malaria cases reported through routine malaria case surveillance data in western Kenya.

Methods

From 23 implementing and 23 comparison subcounties in western Kenya, monthly numbers of confirmed uncomplicated malaria cases among individuals under 5 years of age (< 5y) and 5 years of age and older (≥ 5y) were extracted from the Kenya Health Management Information System, stored in a DHIS2 instance. Facilities that reported data ≥ 11 months per year from January 2015 through December 2022 (132 implementing, 139 comparison) were included in the analysis. Prevaccination data (January 2015–December 2019) were used to predict counterfactual case counts during the evaluation period (January 2020–December 2022), beginning when the first children vaccinated under MVIP became age-eligible for the third dose. Models of < 5y malaria cases included a covariate for ≥ 5y malaria cases to control for non-RTS,S malaria control measures. The impact was estimated as the difference between predicted and observed cases across implementing and comparison areas.

Results

The proportion of vaccine eligible children (RTS,S doses at 6, 7, 9, and 24 months) among all children < 5y was small at the start of MVIP but was estimated to reach 60% by December 2022. During the 3-year evaluation period following dose-3 age-eligibility, < 5y malaria cases were 2.3% lower than predicted in non-implementing facilities and 13.8% lower in implementing facilities, a reduction of 11.6%. The reduction was 5.6% during the first year of follow-up, increasing to 8.2% after two years.

Conclusion

This analysis revealed that routine health data, although age-aggregated to both vaccine eligible and noneligible children < 5 years, demonstrated a reduction in malaria cases throughout the evaluation period. A further reduction in cases was observed as more vaccine-eligible children comprised the under 5 population. High quality routine data can be used to monitor vaccine impact on clinical malaria.